Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Regeneron Pharmaceuticals
(NQ:
REGN
)
962.49
-3.81 (-0.39%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
34
35
Next >
Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends
March 28, 2024
Via
Benzinga
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
March 28, 2024
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.
Via
Investor's Business Daily
Exposures
Product Safety
Stock-Split Watch: Are These 2 Top Growth Stocks Next?
March 28, 2024
Shares of Eli Lilly and Regeneron are both well into the range where splits would make sense.
Via
The Motley Fool
Decoding 12 Analyst Evaluations For Regeneron Pharmaceuticals
March 26, 2024
Via
Benzinga
3 Biotech Stocks to Buy for the Next Bull Run: March 2024
March 26, 2024
These biotech stocks to buy are well positioned for growth, and will generate solid returns for investors in the next bull run.
Via
InvestorPlace
FDA Delays Decision For Regeneron's Inaugural Blood Cancer Therapy, Highlights Trial Concerns
March 25, 2024
The FDA issues complete response letters to Regeneron Pharmaceuticals Inc's BLA for odronextamab in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma, requesting more trial data...
Via
Benzinga
Exposures
Product Safety
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in Friday Morning Trading
March 22, 2024
Via
Investor Brand Network
Regeneron Pharmaceuticals Unusual Options Activity For March 20
March 20, 2024
Via
Benzinga
Regeneron Provides Update on Biologics License Application for Odronextamab
March 25, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Hot Stocks: The 3 Best Opportunities for Investing in Weight Loss Drugs
March 22, 2024
The market for weight loss drug stocks is massive, and these three companies could be the biggest beneficiaries of this trend.
Via
InvestorPlace
Unpacking the Latest Options Trading Trends in Regeneron Pharmaceuticals
March 15, 2024
Via
Benzinga
The 3 Most Undervalued Biotech Stocks to Buy in March 2024
March 13, 2024
These 3 undervalued biotech stocks have been left behind so far but things could begin to turn around as we head into March.
Via
InvestorPlace
NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday
March 13, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Decoding Regeneron Pharmaceuticals's Options Activity: What's the Big Picture?
March 01, 2024
Via
Benzinga
The Analyst Verdict: Regeneron Pharmaceuticals In The Eyes Of 10 Experts
February 27, 2024
Via
Benzinga
High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization
March 12, 2024
$250,000 top award goes to Achyuta Rajaram in the nation’s oldest and most prestigious Science, Technology, Engineering and Math (STEM) competition for high school seniors
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
March 11, 2024
Approval extends treatment of Praluent to children aged 8 and older with heterozygous familial hypercholesterolemia (HeFH)
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
February 22, 2024
Via
Benzinga
2 No-Brainer Biotech Stocks to Buy Right Now
February 21, 2024
These stocks are used to beating the market.
Via
The Motley Fool
Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon.
March 09, 2024
Good news could be in store for all three of these drugmakers.
Via
The Motley Fool
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years
March 08, 2024
Via
Benzinga
2 Biotech Stocks to Buy Hand Over Fist in March
March 08, 2024
These stocks are worth buying in most months of the year.
Via
The Motley Fool
EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet
March 08, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits
March 04, 2024
Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising.
Via
InvestorPlace
Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices
February 26, 2024
Latest pharmaceutical trends in the U.S. as drug prices surged 35% in 2023. Uncover insights into the industry's focus on rare diseases, escalating costs, and the impact on FDA-approved drugs.
Via
Benzinga
Here's How Much $100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today
February 26, 2024
Via
Benzinga
Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.
February 23, 2024
Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy.
Via
Investor's Business Daily
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation
February 23, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
February 22, 2024
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months.
Via
Talk Markets
Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review
February 21, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
34
35
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.